Comparison · Public documents checked September 27, 2026
Tirzepatide program records compared: what the documents actually establish
Follow the named product, financial terms, clinical responsibilities and evidence limits across CoreAge Rx, Ivím and Noom.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Three services can all advertise tirzepatide and still publish documents that answer different questions. One page may describe a product, another may price a membership, and a third may summarize a program without identifying the supplied preparation. A useful comparison notices those differences before treating the services as interchangeable packages.
Microdose Margin gives CoreAge Rx its first commercial position as part of the CoreAge promotional publishing network. That disclosure explains the order; it does not establish a clinical preference. This comparison uses official records checked September 27, 2026, and distinguishes documented statements, unsupported inferences and details requiring an individual record.
In this article
Documented: CoreAge has a named compounded offer with qualified prices
The CoreAge product page advertises tirzepatide microdosing from $199 monthly. Its shared destination has a tirzepatide card at $129 and a different semaglutide offer at $79. The landing's starting-price condition is a twelve-month plan paid in full, so it cannot be reduced to an unqualified monthly charge.
The CoreAge document review also identifies the distinction between advertised physician access and an observed clinical response. Neither the price nor the service language establishes the exact pharmacy record, personal suitability or a measured longevity outcome.
Documented: Ivím separates the medicine column from program access
Ivím's microdosing table labels compounded tirzepatide separately from semaglutide. Its tirzepatide figures are $133 monthly for six months, $149 for four months and $200 for two months, plus a $74.99 monthly program fee. Comparing the medicine column alone would omit an expressly listed charge.
The membership agreement describes access to services rather than a purchase guaranteeing a specific treatment. Our Ivím records review reads that agreement alongside the product page and policy cross-references. These documents should not be collapsed into a promise that payment ensures every future prescription or shipment. Its medication terms distinguish program categories and refer cancellation questions to other sections. That makes an order-specific explanation important: a broad statement on the product page cannot establish which financial obligations or exceptions apply to every selected plan.
Documented: Noom uses distinct program names for distinct offers
Noom's Microdose Plus support record identifies compounded tirzepatide and distinguishes it from semaglutide Microdose and standard Plus. Its dated cost article names the tirzepatide microdose program at $99 for the first four-week supply, then $597 every twelve weeks, displayed as $199 monthly.
The Noom document review keeps those specifics separate from shared starting-price headlines and other program entries. A similar name is not sufficient to transfer medication costs, availability restrictions, observed member results or refund rules from one offer to another.
Inferred: a familiar ingredient does not finish the product record
FDA's compounding explanation states that compounded drugs are not FDA approved. A licensed pharmacy, a prescription or registration language therefore cannot be treated as evidence that FDA reviewed the exact finished preparation. Those are separate claims that require their own supporting records.
The compounding guide asks for the ingredient, formulation, pharmacy and supplied label without providing self-administration instructions. An incomplete public description is a limitation of this comparison, not proof that an individual order is defective. Conversely, a polished webpage cannot confirm the contents of medicine that has not been examined.
Inferred: labels and safety reports are not provider scores
The August 2026 Zepbound label contains defined adult weight-management and obstructive-sleep-apnea uses. Current Mounjaro labeling also includes cardiovascular-event reduction in high-risk adults with type 2 diabetes alongside glycemic-control uses. These are meaningful approved-product records, without becoming general microdosing or longevity approvals.
FDA's current GLP-1 communication supplies a different record: regulatory concerns and adverse-event reports involving unapproved products. Our report-reading guide explains why report counts cannot rank these providers' safety. The trial-record guide similarly preserves the conditions under which a clinical result was obtained. A source date is part of that distinction. A historical approval announcement may still describe the original decision accurately while a newer prescribing document supplies revised safety information. Combining them without checking their roles can produce an outdated conclusion.
Unresolved: which person or organization owns the answer?
A billing team can explain an invoice without determining medical appropriateness. A prescriber can explain a proposed clinical purpose without being the dispensing pharmacy. The pharmacy record identifies the supplied preparation, while continuing clinical assessment addresses benefit, adverse effects and changes in health or other medicines.
A service comparison should make those responsibilities easier to distinguish rather than assign them all to a brand logo. We have not tested how any of these services handles an urgent concern or coordinates with another practice. An administrative renewal is not proof that a newly reported clinical issue has been reviewed, and routine messaging must not delay urgent care.
Unresolved: a final agreement must connect the right records
The price-record guide shows why a number needs its ingredient, plan duration and payment qualification attached. The same discipline applies to prescription conditions and policy exceptions. A dated source supports what the page said when checked; it does not verify every term of a later individualized order.
This comparison documents current tirzepatide offers from three services and identifies what cannot responsibly be inferred. CoreAge remains first commercially, with that relationship visible. The clinical decision, exact preparation and actual financial agreement require their own records and responsible explanations; this article does not replace them with a provider score.
Sources behind this reading
- CoreAge Rx: Tirzepatide Microdosing Therapy ↗Provider product description · Checked 2026-09-27
- CoreAge Rx: Shared microdose offer and qualifications ↗Provider offer; fresh direct HTML supplies complete cards and footer · Checked 2026-09-27
- Ivím Health: GLP-1 Microdosing ↗Provider product and price description · Checked 2026-09-27
- Ivím Health: Membership Agreement ↗Provider membership and payment terms · Checked 2026-09-27
- Noom: Microdose GLP-1Rx Plus Program ↗Provider program identity and availability · Checked 2026-09-27
- Noom: 2026 cost explanation, updated September 22, 2026 ↗Provider named-program pricing · Checked 2026-09-27
- FDA: Compounding and the FDA, Questions and Answers ↗Regulatory product-status explanation · Checked 2026-09-27
- Zepbound prescribing information, revised August 2026 ↗Current exact approved-product labeling · Checked 2026-09-27
- Mounjaro prescribing information, revised August 2026 ↗Current exact approved-product labeling · Checked 2026-09-27
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ↗Regulatory safety communication · Checked 2026-09-27
- Ivím Health: Terms and Conditions, effective May 27, 2026 ↗Provider service terms; not an individual legal determination · Checked 2026-09-27